This is a two part study (screening and treatment). The first part (screening) is designed to evaluate the percentage of patients missed in diagnosing osteoporosis by general practitioners (GP's). The second part (treatment) is designed to determine the preference by patients for the once monthly ibandronate or the once weekly alendronate.
A multi-centre, randomised, open-label, cross-over study to evaluate the percentage of false negative osteoporosis diagnoses using the standard case-finding procedure as described by the Dutch Institute for Health Care (CBO) and to determine the preference of adult osteoporosis patients between once monthly dosing of ibandronate (150 mg) and once weekly dosing of alendronate (70 mg).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
300
Part 1: Percentage of patients falsely not diagnosed with osteoporosis using the standard case-finding and additional X-ray procedure in GP practice. Part 2: Patient preference for once monthly ibandronate or once weekly alendronate
Part 1: To assess the safety and tolerance of both ibandronate and alendronate. Part 2: To assess patient preference in reminder methods during once monthly ibandronate regimen: postcard, text message or telephone patient relationship program.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Bennebroek, Netherlands
GSK Investigational Site
Breda, Netherlands
GSK Investigational Site
Damwoude, Netherlands
GSK Investigational Site
Driebergen-Rijsenburg, Netherlands
GSK Investigational Site
Eersel, Netherlands
GSK Investigational Site
Eindhoven, Netherlands
GSK Investigational Site
Enschede, Netherlands
GSK Investigational Site
Etten-Leur, Netherlands
GSK Investigational Site
Geleen, Netherlands
GSK Investigational Site
Groesbeek, Netherlands
...and 28 more locations